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EDITORIAL 
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This themed issue of the British Journal of Pharmacology stems from an International 
Narcotics Research Conference (INRC) Meeting held in July 2016 at The Assembly Rooms in 
Bath, UK. 
 
Opium has been used in society for thousands of years and in more recent times opioid 
drugs have become a mainline treatment for moderate to severe pain, but these drugs are 
also well known for their ability to lead to drug abuse and death due to opioid poisoning. 
There are four opioid receptors named µ, δ, κ and nociceptin, and all are GPCRs. 
Therapeutically, opioid drugs such as morphine are also of pharmacological interest as they 
represent (along with e.g. β-adrenoceptor agonists) one of the few major classes of 
therapeutic drug that are agonists at GPCR targets. This explains in part the interest in 
opioid tolerance and its relationship to GPCR desensitization mechanisms. Nevertheless, 
opioid receptor antagonist drugs are also important drugs, with for example naloxone being 
an essential drug to reverse opioid agonist-induced respiratory depression in opioid 
overdose. Apart from these generally widely recognised aspects of opioids, in recent years 
other less familiar aspects of endogenous opioid systems and opioid drug action have 
emerged. These lesser known but increasingly important areas represent the central theme 
of this issue of British Journal of Pharmacology.  
 
The immune system and its relationship to opioid function is one such emergent area. Plein 
and Rittner (2017) report that whilst it is generally belived that opioid drugs exert an 
immunosuppressive effect in patients,  some immune cells also release opioid peptides 
which can reduce inflammation and pain. However further studies at the clinical and 
epidemiological level are required to determine the importance of such interactions to the 
patient. Opioid drugs are often prescribed to manage pain in cancer, but as described by 
Boland and Pockley (2017) opioids can also affect the entry of immune cells into the tumour 
micro-environment. Some of these effects vary with the exact opioid drug being employed 
whilst some of the effects of opioid drugs on immune cells may be mediated by non-opioid 
receptor mechanisms. Their review highlights that further studies are needed to determine 
clinical outcomes in defined cancer patient groups.   
 
Opioid receptors, particularly µ receptors, are well expressed in the mammalian brain 
emotion circuitry. As discussed by Nummenmaa and Tuominen (2017) both endogenous 
opioid systems and exogenous opioid drugs are considered to contribute to a wide array of 
positive and negative emotions, and thus are suggested to play an important role in in 
psychological and psychosomatic resilience. Pellissier et al. (2017) describe how in µ opioid 
receptor null mice, the behavioural defecits observed are similar to those observed in 
patients with autism spectrum disorder (ASD), such as poor social interactions. It is 
suggested that altered µ opioid receptor function may contribute to this pathology in ASD. 
 
Whilst opioids have long been known for their ability to suppress acute pain, nevertheless 
new aspects of this theme continue to surface, for example in the area of chronic pain. 
There is an important relationship between pain and reward, with the obvious problem of 
dealing with opioid pain therapy in subjects with substance abuse disorder, as discussed by 
Wilson-Poe and Morón (2017). In particular more work is needed to understand the 
interaction between chronic pain and the brain’s reward system. On the other hand Jones 
and Brown (2017) argue for the application of quantitative computational models to analyse 
neuroplasticity in chronic pain. They discuss the role of predictive mechanisms in different 
types of plasticity, and evidence for their modulation by endogenous opioids. One further 
contribution to the discussion of opioids in chronic pain is provided by Maldonado et al. 
(2017), who describe the effects of various gene knockouts in mice of components of the 
opioid system (receptors or peptides) on models of chronic pain. The data from such studies 
have suggested, for example, the development of novel opioid drugs which target multiple 
opioid receptor subtypes. This latter theme is returned to again in this editiorial below.  
 
Other emergent themes in the opioid field include the use of the neurohypophyseal peptide 
oxytocin or other oxytocinergic drugs to treat opioid addiction and co-existing affective 
disorders, as described by Zanos et al. (2017). Oxytocin is known for its strong effects on 
mediating reward, social interaction, stress and learning/memory, and whilst the preclinical 
data support the use of oxytocinergics to manage drug addicition, further clinical studies are 
needed to take this concept forward. Another field of interest coming to the fore is the 
complex regulation of neuronal systems within subdomains of brain nuclei previously 
considered to be relatively homogenous. For the ventral tegmental area, as discussed by 
Thomas et al. (2017), both µ and κ opioid receptors regulate distinct populations in this 
nuclei, the former regulating presynaptic activity and the latter postsynaptic dopaminergic 
neuronal activity. The precise selectivity of endogenous opioid peptides and exogenous 
opioid drugs is therefore critical in determining the functional output of such brain regions. 
 
 
Finally new aspects of the molecular pharmacology of opioid receptors are gaining 
increasing interest. Molecular Dynamics simulations afford an unprecedented and 
increasingly important insight into the dynamic interaction of ligands with opioid receptors, 
ligand-induced conformational changes, as well as the likely nature of the interactions in 
receptor dimers (Marino et al. 2017). These in silico studies have been made possible by the 
availability of crystal structures of the opioid receptors. Small molecule allosteric 
modulators, particularly at mu and delta opioid receptors, have been identified with the 
idea of modifying the effects of endogenous opioids and avoiding many of the adverse 
effects seen with exogenous opioid drugs (Livingston and Traynor, 2017). Allosteric 
modulators interact with regions of the receptor other than the orthosteric site occupied by 
the endogenous opioid peptides or most exogenous ligands, and can exert positive or 
negative effects on signalling (Positive Allosteric Modulators or PAMs, and Negative 
Allosteric Modulators or NAMs, respectively). Other emerging approaches in an attempt to 
enhance the effectiveness of opioid drug therapy whilst limiting the adverse effects include 
the targeting of multiple opioid receptors with a single chemical entity (Günther et al., 
2017). The drug dihydroetorphine for example is a strong agonist at µ, δ and κ receptors 
whilst subtler effects include those of nalfurafine, a κ receptor agonist with weak effects at 
µ and δ receptors and which exerts antipruritic as well as analgesic effects. This theme is 
developed by Almatroudi et al. (2017) who report a mixed κ/µ receptor antagonist, 
BU10119, which has potential as a treatment for depression and stress-related disorders, 
and the work of Dietis et al. (2018) who report on the analgesic actions and tolerance 
liability of the experimental drug UFP-505, which has µ agonist activity along with very weak 
partial agonism/antagonism at δ receptors. 
 
This themed section highlights the diversity of current research in opioid pharmacology. No 
longer are opioids involved only in pain and euphoria but are increasingly being implicated 
in a wide range of physiological systems and disease states. The organizers would like to 
thank all the presenters and sponsors of INRC 2016 (tinyurl.com/yacasw9u), especially BPS 
and NIDA, for making it such a stimulating conference. 
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